← Back to Briefing
Owkin Licenses AI Platform and Multimodal Data to Servier for Oncology Research; AI Addresses Missing Real-World Data
Importance: 85/1003 Sources
Why It Matters
This collaboration highlights the growing role of AI and comprehensive real-world data in enhancing the efficiency and accuracy of oncology research, which can lead to faster development of new cancer treatments and improved patient outcomes.
Key Intelligence
- ■Owkin has licensed its K Pro AI Scientist platform and multimodal patient data to Servier.
- ■The agreement aims to accelerate oncology research and drug development by leveraging advanced AI and real-world data.
- ■Separately, an AI model is being developed to address missing ECOG performance status, a crucial clinical measure, in real-world oncology datasets.
Source Coverage
Google News - Research
9/11/2026Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research - Via TT
Google News - AI & Models
9/11/2026AI Model Could Help Address Missing ECOG Performance Status in Real-World Oncology Data - Pharmacy Times
Google News - Research
9/11/2026